Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 71Colorectal Neoplasms 34Rectal Neoplasms 33Esophageal Neoplasms 25Carcinoma, Non-Small-Cell Lung 24Esophageal Squamous Cell Carcinoma 23Pancreatic Neoplasms 16Stomach Neoplasms 15Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Adenocarcinoma Of Esophagus 14Sarcoma 11Ovarian Neoplasms 11Lung Neoplasms 11Colonic Neoplasms 11Carcinoma, Hepatocellular 11Prostatic Neoplasms 10Head and Neck Neoplasms 10Neoplasm Metastasis 9Urinary Bladder Neoplasms 8Uterine Cervical Neoplasms 7Recurrence 6Osteosarcoma 6Multiple Myeloma 5Fallopian Tube Neoplasms 5Carcinoma, Intraductal, Noninfiltrating 5Breast Carcinoma In Situ 5Peritoneal Neoplasms 4Nasopharyngeal Carcinoma 4Locally Advanced Rectal Cancer 4

Interventions

Nivolumab 3Cisplatin 2Albumin-Bound Paclitaxel 2tislelizumab 1spartalizumab 1Taxes 1Standard of Care 1Radiotherapy 1Neoadjuvant Therapy 1Immunotherapy 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Muscle-Invasive Bladder Carcinoma × Neoadjuvant Therapy × Clear all
NCT06325423 2024-03-26

Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

Assiut University

Not yet recruiting
50 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡